Novo Nordisk sues Eli Lilly: GLP-1 advertisement accused of "bullying," is the weight-loss drug market changing?
The global GLP-1 weight loss drug market competition is escalating further.
On July 21, it was reported that Novo Nordisk has taken Eli Lilly to court in the United States, accusing it of misleading patients through "high dose vs. low dose" comparisons in consumer-targeted advertisements and engaging in